Miguel Moreno

Miguel Moreno received his Ph.D. in 2005 at the University of Alcala de Henares where he developed electrochemical DNA biosensors based on DNA-gold capped nanoparticles. As part of his Master degree, he selected aptamers against a protein of Leishmania infantum. In 2003 he joined the group of Prof. Carlos Martinez A. (CNB-CSIC) to develop DNA arrays based on nanocantilevers in close collaboration with the group of Prof. Laura Lechuga (IMM-CNM-CSIC). In 2006 he moved to Prof. David Russell’s group at the University of East Anglia (UK) where he was involved in the development of gold nanoparticles as drug carriers for in vivo PDT. In 2007 he co-founded Bioapter, a novel technological company based on the development of aptamers based biosensors and therapies. In October 2009 he joined the group of Carlos Briones at the Astrobiology Centre in Madrid (CAB, CSIC-INTA, Associated to the NASA Astrobiology Institute) where he is currently exploring the origin of life including experimental approaches to the RNA world hypothesis, in vitro selection and evolution of nucleic acids (RNA and DNA aptamers), bionanotechnology-inspired biosensors (DNA microarray technology, PNA- and aptamer-based sensors,) and sequence-structure-function relationships in viral genomic RNA studied by AFM. In January 2020 he joined Aptus Biotech as CSO. As an expert in aptamer technology he is responsible of implement new projects and business to the company. Author of 30 articles in international peer reviwed journals, 5 chapters in specialized books, and more than 60 communications to international conferences.